All Valeant articles
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
BusinessFemale sexual desire drug approved
Concerns raised over efficacy, side effects and use of advocacy campaigning to influence regulatory decisions
-
Business
Valeant heads off Endo bid for Salix
Bid raised to $15.8 billion in cash after rival offer from Irish firm
-
Business
Valeant to buy Salix for $14.5bn
Companies expect $500m in savings through ‘R&D rationalisation’
-
-
BusinessActavis rescues Allergan with $66 billion deal
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price
-
BusinessTakeover battle pushes Allergan to cut R&D jobs
Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth
-
Business
Thousands face job cuts after Valeant's Bausch buyout
Valeant plans to shed 10-15% of its workforce to save $800 million